# OnCo record extranodal-nk-t-cell-lymphoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/extranodal-nk-t-cell-lymphoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "extranodal-nk-t-cell-lymphoma" ;
  schema:name "Extranodal NK/T-cell lymphoma"@en ;
  schema:alternateName "Extranodal NK/T-cell lymphoma, nasal type"@en, "ENKTL"@en, "ENKTCL"@en, "Nasal type NK/T-cell lymphoma"@en, "NK/T-cell lymphoma"@en, "Lethal midline granuloma"@en, "Angiocentric lymphoma"@en, "Extranodal NK/T-cell lymphoma (EBV)"@en ;
  schema:description "An aggressive lymphoma of natural killer cells, always driven by Epstein-Barr virus, that destroys the tissues in the middle of the face: the nose, the palate and the sinuses. It is common in east Asia and Latin America and uncommon in Europe, and it is the one lymphoma in which ordinary anthracycline chemotherapy does not work at all."@en ;
  schema:url <https://onco.cc/cancers/extranodal-nk-t-cell-lymphoma/> ;
  schema:dateModified "2026-09-29"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Extranodal_NK/T-cell_lymphoma,_nasal_type> ;
  schema:citation <https://doi.org/10.1038/s41375-022-01620-2>, <https://doi.org/10.1182/blood.2022015851>, <https://doi.org/10.1016/S1470-2045(15)00533-1>, <https://doi.org/10.1007/s11899-016-0355-9>, <https://doi.org/10.1371/journal.pone.0315380>, <https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq> ;
  onco:tag "heme", "lymphoma", "subtype-page" ;
  onco:related <https://onco.cc/cancers/peripheral-t-cell-lymphoma/>, <https://onco.cc/cancers/adult-t-cell-leukaemia-lymphoma/>, <https://onco.cc/cancers/nasopharyngeal/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/>, <https://onco.cc/cancers/hepatosplenic-t-cell-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/allogeneic-hsct/> ;
  onco:drugs <https://onco.cc/drugs/asparaginase/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/> ;
  onco:terms <https://onco.cc/terms/ebv-term/>, <https://onco.cc/terms/plasma-ebv-dna/>, <https://onco.cc/terms/lymphoma-classification-2022/>, <https://onco.cc/terms/lymphoma-nodal-versus-extranodal/>, <https://onco.cc/terms/lymphoma-pit-score/>, <https://onco.cc/terms/lymphoma-tx-radiotherapy/>, <https://onco.cc/terms/lymphoma-b-versus-t-cell/>, <https://onco.cc/terms/lymphoma-tx-regimen-alphabet/> ;
  onco:standardOfCare <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/terms/ebv-term/>, <https://onco.cc/terms/endoscopy/>, <https://onco.cc/terms/lymphoma-classification-2022/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/terms/plasma-ebv-dna/>, <https://onco.cc/terms/lugano-classification/>, <https://onco.cc/terms/ebv-term/>, <https://onco.cc/drugs/asparaginase/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/ifosfamide/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/dexamethasone/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/oxaliplatin/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/terms/lymphoma-tx-radiotherapy/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/terms/ebv-term/>, <https://onco.cc/terms/plasma-ebv-dna/>, <https://onco.cc/technologies/allogeneic-hsct/> .